No Data
MEDINET Co., Ltd. Reports Financial Challenges in Q1 2024
Medinet: Summary of financial results for the 1st quarter of the fiscal year ending September 2025 [Japanese GAAP] (unconsolidated)
MDNT Research Memo (8): Under 'VISION2030', the second medium-term management plan is being promoted.
■ Medinet <2370> mid-term management plan 1. Overview of the second mid-term management plan Since April 2022, the management leadership has transitioned from founder Mr. Kimura to Mr. Kuhiro, and they are advancing discussions on a new mid-term management plan that incorporates new perspectives and points of discussion. The company announced "VISION2030," a corporate vision aimed at 2030 (the desired state of the company ten years later), and is utilizing a backcasting approach (a method that traces the path from the future to the present) to develop "VISION203.
MDNT Research Memo (2): A biotech venture in the field of "cancer immune cell therapy." Promoting corporate transformation.
■Company Overview of Medinetwork <2370> 1. History (1) Foundation The company is a pioneer in the field of "cancer immunotherapy" and is a biotech venture. The current Chairman, Mr. Kimura, was responsible for the sales of contact lenses and Medical Devices at Hoya Glass Co., Ltd. (now HOYA <7741>), which led to the founding of the company in 1995 to develop and commercialize cancer immunotherapy. Subsequently, Mr. Kimura has been researching cancer immunotherapy with Dr. Egawa at the University of Tokyo Institute of Medical Science.
Volume change rate ranking (9 AM) - Onward HD, BTM, ETC are ranked.
By comparing the average volume over the last 5 days with the volume on the day of distribution in the Volume Change Rate Ranking, it is possible to understand the trends in buying and the interests of market participants. ■ Top Volume Change Rates [As of January 9, 9:32 AM] (Comparison of the average volume over the last 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate ＜3656＞KLab 2010300 107185.08 104.51% -0.1785%
Medinet: Extraordinary Report